Why I Went Into Radiation Oncology

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

May 1st 2025

Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Concurrent Chemoradiation May Improve LS-SCLC Prognosis

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

"Early [concurrent] CRT provides a significant survival benefit, while late [concurrent] CRT is an acceptable option," according to the study authors.

Russ Conroy

71 Beyond the Surface: Suspicious Nipple Lesions

Whole-brain prophylactic cranial irradiation appears to confer minimal overall survival benefits in those with limited-stage small cell lung cancer.

Related Content

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Frontline ICI Therapy Confers OS Benefit in MSI-H Metastatic CRC

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS

May 1st 2025

Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

Concurrent Chemoradiation May Improve LS-SCLC Prognosis

Phase 2 Actuate-1801 part 3B trial results evaluating elraglusib with GnP in metastatic PDAC will be presented at the 2025 ASCO Annual Meeting.

Russ Conroy